Brokerages Set Esperion Therapeutics, Inc. (NASDAQ:ESPR) Price Target at $7.00

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) have earned a consensus recommendation of “Moderate Buy” from the six ratings firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $7.00.

A number of brokerages have recently issued reports on ESPR. HC Wainwright reiterated a “buy” rating and set a $16.00 target price on shares of Esperion Therapeutics in a research report on Friday, September 19th. Wall Street Zen raised Esperion Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, September 26th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Esperion Therapeutics in a research note on Wednesday, October 8th.

Esperion Therapeutics Stock Performance

Esperion Therapeutics stock opened at $2.82 on Tuesday. The business’s fifty day moving average is $2.51 and its two-hundred day moving average is $1.59. The firm has a market cap of $568.57 million, a P/E ratio of -5.76 and a beta of 0.96. Esperion Therapeutics has a 52 week low of $0.69 and a 52 week high of $3.94.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.15. The business had revenue of $82.39 million during the quarter, compared to the consensus estimate of $62.55 million. On average, equities research analysts predict that Esperion Therapeutics will post -0.29 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. DHJJ Financial Advisors Ltd. raised its position in Esperion Therapeutics by 209.2% in the 3rd quarter. DHJJ Financial Advisors Ltd. now owns 9,430 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 6,380 shares during the last quarter. Sivia Capital Partners LLC boosted its holdings in Esperion Therapeutics by 47.4% during the third quarter. Sivia Capital Partners LLC now owns 37,929 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 12,191 shares during the last quarter. CWM LLC grew its position in Esperion Therapeutics by 46.5% in the third quarter. CWM LLC now owns 19,674 shares of the biopharmaceutical company’s stock valued at $52,000 after purchasing an additional 6,249 shares in the last quarter. Sanders Morris Harris LLC acquired a new position in shares of Esperion Therapeutics during the 3rd quarter worth about $53,000. Finally, State of Wyoming grew its holdings in shares of Esperion Therapeutics by 36.2% in the 2nd quarter. State of Wyoming now owns 122,532 shares of the biopharmaceutical company’s stock valued at $121,000 after acquiring an additional 32,596 shares in the last quarter. 47.39% of the stock is currently owned by institutional investors.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.